PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-55.65%
Both yoy net incomes decline, with VET at -610.43%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
2.44%
Some D&A expansion while VET is negative at -5.46%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-72.15%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
105.88%
SBC growth well above VET's 6.65%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-172.73%
Negative yoy working capital usage while VET is 133.59%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
207.02%
AR growth of 207.02% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-172.73%
Negative yoy usage while VET is 133.59%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
29.17%
Lower 'other non-cash' growth vs. VET's 586.10%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-16.56%
Negative yoy CFO while VET is 34.40%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
24.53%
Some CapEx rise while VET is negative at -30.93%. John Neff would see competitor possibly building capacity while we hold back expansions.
1073.33%
Acquisition spending well above VET's 100.00%. Michael Burry would suspect heavier integration risk or short-term free cash flow drain vs. competitor.
-373.33%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
-373.33%
Both yoy lines negative, with VET at -103.27%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
29.31%
We have mild expansions while VET is negative at -40.52%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
91.75%
We repay more while VET is negative at -97.82%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
66.56%
Buyback growth of 66.56% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.